The company said revenues from its ConfirmMDx prostate cancer test rose 62 percent in 2015, and that testing volume exceeded 15,000 patients.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The multinational healthcare company expects revenue of $16 million to $20 million for the year and said it performed 15,000 to 17,000 tests in 2015.
The deal gives SouthGenetics marketing rights for MDxHealth's ConfirmMDx test for prostate cancer in 12 countries, including Mexico, Argentina, and Colombia.
Case volume for its ConfirmMDx for Prostate Cancer test increased 30 percent to more than 4,500 tests compared to 3,500 tests in Q3 2014.
The firm's SelectMDx prostate cancer test will be used in conjunction with MRI to evaluate their combined effectiveness in nominating patients for prostate biopsy.
The deal provides Tufts Health Plan members with access to the ConfirmMDx test for prostate cancer.
NovioGendix is focused on developing a liquid biopsy prostate cancer test to identify patients at low risk for the disease.
Though ConfirmMDx volume was flat year over year, increased payor coverage and efforts to collect payments grew test revenues 77 percent.
The company is developing a liquid biopsy test using the methylation markers, and will report preliminary data at an upcoming urological research meeting.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.